BY INTRAVENOUS INFUSION, ADULT OVER 18 YEARS, BODY-WEIGHT LESS THAN 60 KG, 500 MG, REPEATED 2 WEEKS AND 4 WEEKS AFTER INITIAL INFUSION, THEN EVERY 4 WEEKS; BODY-WEIGHT 60 -100 KG, 750 MG REPEATED 2 WEEKS AND 4 WEEKS AFTER INITIAL INFUSION, THEN EVERY 4 WEEKS; BODY-WEIGHT OVER 100 KG, 1 G REPEATED 2 WEEKS AND 4 WEEKS AFTER INITIAL INFUSION, THEN EVERY 4 WEEKS.
MAY BE USED AS MONOTHERAPY OR CONCOMITANTLY WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD) OTHER THAN TUMOR NECROSIS FACTOR (TNF) ANTAGONISTS. SHOULD NOT BE USED WITH OTHER BIOLOGIC RA THERAPY SUCH AS ANAKINRA
PRIOR TO INITIATING IMMUNOMODULATORY THERAPIES, INCLUDING ORENCIA, PATIENTS SHOULD BE SCREENED FOR LATENT TUBERCULOSIS INFECTION WITH A TUBERCULIN SKIN TEST. ANTI-RHEUMATIC THERAPIES HAVE BEEN ASSOCIATED WITH HEPATITIS B REACTIVATION. THEREFORE, SCREENING FOR VIRAL HEPATITIS SHOULD BE PERFORMED
CHILDREN: GIVEN BY IV ROUTE
6 YRS OR MORE & <75 KG: 10 MG / KG , REPEAT DOSE AT 2 WKS & 4 WKS AFTER INITIAL INFUSION, & EVERY 4 WK THEREA FTER.